Obesity

CagriSema: what is it, and what do the trials show?

CagriSema combines semaglutide with an amylin analogue. What REDEFINE 1 and 2 found on weight and HbA1c, the side effects, and where approval stands.

The short answer

CagriSema is a once-weekly injection that combines semaglutide with cagrilintide, a copy of the hormone amylin. In people with type 2 diabetes it lowered weight by about 14% and brought HbA1c to 6.5% or below in nearly three in four.

It isn’t approved yet. Novo Nordisk applied to the US regulator in December 2025 for weight management and expects a decision in late 2026. Stomach side effects are common.

Here’s what’s in it, what the trials found, and what it means if you have diabetes.

What is CagriSema?

Two medicines in one weekly jab.

Semaglutide is the same medicine as in Ozempic and Wegovy. It’s a GLP-1 medicine: it reduces appetite, slows the stomach and helps the pancreas release insulin when sugar is high.

Cagrilintide is new. It copies amylin, a hormone your beta cells release alongside insulin after a meal. Amylin also helps you feel full and slows how fast food leaves the stomach.

The idea is that two fullness signals work better than one. The trial dose is 2.4 mg of each, reached by stepping up slowly over about 16 weeks.

What did the trials show?

The two main trials ran for 68 weeks and were published in 2025.

REDEFINE 1 REDEFINE 2
Who 3,417 adults with overweight or obesity, no diabetes 1,206 adults with type 2 diabetes, BMI 27 or more, HbA1c 7 to 10%
Weight change on CagriSema Down 20.4% Down 13.7%
Weight change on placebo Down 3.0% Down 3.4%
HbA1c Not the main question 6.5% or below in 73.5%, against 15.9% on placebo

In REDEFINE 1, people who kept taking it as planned lost an average of 22.7%.

Notice the gap. People with type 2 diabetes lost less weight than people without it. That’s a pattern seen with every medicine in this group, not just this one.

What are the side effects?

Mostly the stomach. In REDEFINE 1, about 8 in 10 people on CagriSema had a stomach side effect, against 4 in 10 on placebo.

  • Nausea: 55%
  • Constipation: 31%
  • Vomiting: 26%

Most of it was mild to moderate and happened while the dose was going up. About 6 to 8 in 100 people stopped because of side effects.

Because it contains semaglutide, it’s expected to carry the same warnings as that medicine, including gallbladder problems and pancreatitis. See diabetes, gallstones and GLP-1 medicines.

Is it approved?

Not yet. Novo Nordisk asked the US Food and Drug Administration to approve it on 18 December 2025. The application is for long-term weight management, not specifically for diabetes.

In November 2026 the company said it still expected a decision in the last quarter of the year, and that CagriSema isn’t approved in the US.

So it isn’t something your doctor can prescribe today. Anything sold online as CagriSema isn’t the trial medicine. Don’t buy it.

Would it suit someone with type 2 diabetes?

Possibly, if it’s approved. REDEFINE 2 is the trial that matters for you, and the HbA1c results were strong.

A few things to know:

  • Hypos. On its own it rarely causes them. With insulin or a sulfonylurea such as gliclazide, those doses may need lowering.
  • It’s long term. With medicines like this, weight usually comes back when they’re stopped.
  • It isn’t the only option. Semaglutide and tirzepatide are available now and also lower weight and HbA1c.

More on what’s available now: Ozempic for type 2 diabetes and your first month on semaglutide.

Should I wait for it?

Usually not. If your weight or HbA1c needs treating now, treat it with what’s available now. If CagriSema is approved and suits you better later, a switch can be discussed then.

The bottom line

CagriSema adds an amylin copy to semaglutide. In trials it gave some of the biggest weight losses seen with a weekly injection, and good HbA1c results in type 2 diabetes.

It’s still waiting for approval. Watch this space, but don’t put your treatment on hold for it.

More in our diabetes medications guide.

Sources

General public information, not personalised treatment advice. Children, pregnancy and complex health conditions need individual specialist advice. Don’t start, stop or change a medicine without speaking to your own healthcare team.

Spread the love

Leave a comment